Sinjard-L 25/5 

Presentation: Sinjard-L 25/5 is presented as tablets containing 25mg of empagliflozin and 5mg of linagliptin. The tablets are usually film-coated and available in blister packs. The appearance (shape, color, markings) may vary depending on the manufacturer in Bangladesh (e.g., Beacon Pharmaceuticals PLC).

Indications: Sinjard-L is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus whentreatment with both empagliflozin and linagliptin is appropriate.  

Dosage and Administration: The recommended dose is one tablet (empagliflozin 10 mg and linagliptin 5 mg) once daily, taken in the morning, with or without food. The dose may be increased to one tablet containing empagliflozin 25 mg and linagliptin 5 mg once daily in patients who are tolerating the initial dose and require further glycemic control.

Assess renal function before initiating Sinjard-L. It is not recommended in patients with an eGFR below 45 mL/min/1.73 m². Discontinue if eGFR falls below this level. Follow your doctor's specific instructions.

Side Effects: Common side effects may include urinary tract infections, nasopharyngitis, and increased urination. When used with insulin or sulfonylureas, there is an increased risk of hypoglycemia. Other potential side effects include genital mycotic infections, dehydration, and hypotension.

Tell your doctor promptly if you experience any unusual or severe side effects, including symptoms of pancreatitis, ketoacidosis, or severe allergic reactions.

Precautions: Sinjard-L is contraindicated in patients with severe renal impairment, end-stage renal disease, or dialysis, and in patients with a history of hypersensitivity reactions to empagliflozin or linagliptin.

Caution should be exercised in patients with moderate renal impairment, heart failure, and those at risk of volume depletion. Monitor renal function periodically. Avoid excessive alcohol consumption.

Use during pregnancy is generally not recommended, especially in the second and third trimesters. Breastfeeding is also not recommended.

Inform your doctor about all other medications you are taking, including herbal supplements, as there may be potential drug interactions.

Storage: Store Sinjard-L tablets in a cool and dry place, protected from light and moisture, below 30°C. Keep out of reach of children.

Important Note: This information is for general knowledge and informational purposes only, and does not substitute professional medical advice. Always consult your doctor or pharmacist for specific instructions and guidance regarding your medication. They can assess your individual medical condition and provide the most appropriate advice.